A human bone morphogenetic protein antagonist is down-regulated in renal cancer.

We analyzed expression of candidate genes encoding cell surface or secreted proteins in normal kidney and kidney cancer. This screen identified a bone morphogenetic protein (BMP) antagonist, SOSTDC1 (sclerostin domain-containing-1) as down-regulated in kidney tumors. To confirm screening results, we probed cDNA dot blots with SOSTDC1. The SOSTDC1 message was decreased in 20/20 kidney tumors compared with normal kidney tissue. Immunohistochemistry confirmed significant decrease of SOSTDC1 protein in clear cell renal carcinomas relative to normal proximal renal tubule cells (p < 0.001). Expression of SOSTDC1 was not decreased in papillary and chromophobe kidney tumors. SOSTDC1 was abundantly expressed in podocytes, distal tubules, and transitional epithelia of the normal kidney. Transfection experiments demonstrated that SOSTDC1 is secreted and binds to neighboring cells and/or the extracellular matrix. SOSTDC1 suppresses both BMP-7-induced phosphorylation of R-Smads-1, -5, and -8 and Wnt-3a signaling. Restoration of SOSTDC1 in renal clear carcinoma cells profoundly suppresses proliferation. Collectively, these results demonstrate that SOSTDC1 is expressed in the human kidney and decreased in renal clear cell carcinoma. Because SOSTDC1 suppresses proliferation of renal carcinoma cells, restoration of SOSTDC1 signaling may represent a novel target in treatment of renal clear cell carcinoma.

[1]  S. Guidato,et al.  Wise retained in the endoplasmic reticulum inhibits Wnt signaling by reducing cell surface LRP6. , 2007, Developmental biology.

[2]  Mala Sinha,et al.  Secreted Frizzled-Related Protein 1 Loss Contributes to Tumor Phenotype of Clear Cell Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[3]  Anne-Claude Gingras,et al.  Wilms Tumor Suppressor WTX Negatively Regulates WNT/ß-Catenin Signaling , 2007, Science.

[4]  James Brugarolas,et al.  Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.

[5]  O. Iliopoulos.  Molecular biology of renal cell cancer and the identification of therapeutic targets. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Vrieling,et al.  Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP‐Stimulated Bone Formation , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  Howard Y. Chang,et al.  Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation , 2006, Proceedings of the National Academy of Sciences.

[8]  M. Yanagita.  Modulator of bone morphogenetic protein activity in the progression of kidney diseases. , 2006, Kidney international.

[9]  K. Miyazono,et al.  Execution of BMP-4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell hybridoma cells , 2006, Oncogene.

[10]  P. Kauraniemi,et al.  Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer , 2006, Genes, chromosomes & cancer.

[11]  R. Fodde,et al.  Smad4 haploinsufficiency in mouse models for intestinal cancer , 2006, Oncogene.

[12]  E. Schwarz,et al.  Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. , 2006, Bone.

[13]  Katsu Takahashi,et al.  Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. , 2005, The Journal of clinical investigation.

[14]  Nobuyuki Itoh,et al.  Regulation of Mammalian Tooth Cusp Patterning by Ectodin , 2005, Science.

[15]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[16]  C. Heldin,et al.  Smad pathway‐specific transcriptional regulation of the cell cycle inhibitor p21WAF1/Cip1 , 2005, Journal of cellular physiology.

[17]  M. Herlyn,et al.  Bone morphogenetic proteins in melanoma: Angel or devil? , 2005, Cancer and Metastasis Reviews.

[18]  M. Yanagita.  BMP antagonists: their roles in development and involvement in pathophysiology. , 2005, Cytokine & growth factor reviews.

[19]  W Marston Linehan,et al.  The genetic basis of cancer of kidney cancer: implications for gene‐specific clinical management , 2005, BJU international.

[20]  K. Miyazono,et al.  BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells , 2004, Oncogene.

[21]  Di Chen,et al.  Bone Morphogenetic Proteins , 2004, Growth factors.

[22]  Z. You,et al.  Bone Morphogenetic Protein (BMP)-6 Signaling and BMP Antagonist Noggin in Prostate Cancer , 2004, Cancer Research.

[23]  Ossama Tawfik,et al.  BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt–β-catenin signaling , 2004, Nature Genetics.

[24]  Philippe Soriano,et al.  In vivo convergence of BMP and MAPK signaling pathways: impact of differential Smad1 phosphorylation on development and homeostasis. , 2004, Genes & development.

[25]  A. Niida,et al.  USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. , 2004, Biochemical and biophysical research communications.

[26]  Nobuyuki Itoh,et al.  Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. , 2003, Developmental biology.

[27]  Alison Rowe,et al.  Wise, a context-dependent activator and inhibitor of Wnt signalling , 2003, Development.

[28]  Ajamete Kaykas,et al.  Zebrafish Prickle, a Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastrulation Movements , 2003, Current Biology.

[29]  D. Blair,et al.  Drm/Gremlin transcriptionally activates p21(Cip1) via a novel mechanism and inhibits neoplastic transformation. , 2002, Biochemical and biophysical research communications.

[30]  C. Heldin,et al.  Smad regulation in TGF-beta signal transduction. , 2001, Journal of cell science.

[31]  N. Heldin,et al.  BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). , 2001, Biochemical and biophysical research communications.

[32]  K. Miyazono,et al.  Divergence and convergence of TGF‐β/BMP signaling , 2001, Journal of cellular physiology.

[33]  U. Vitt,et al.  Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. , 2001, Molecular endocrinology.

[34]  A. Reddi.  Bone Morphogenetic Proteins: From Basic Science to Clinical Applications , 2001, The Journal of bone and joint surgery. American volume.

[35]  A. Celeste,et al.  Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. , 2000, Biochemical and biophysical research communications.

[36]  K. Miyazono.  TGF-β signaling by Smad proteins , 2000 .

[37]  K. Miyazono,et al.  Signal transduction by bone morphogenetic proteins. , 1998, Cytokine & growth factor reviews.

[38]  David A. Mankoff,et al.  Application of Photoshop-based Image Analysis to Quantification of Hormone Receptor Expression in Breast Cancer , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[39]  J. Smith,et al.  Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects , 1995, The Journal of cell biology.

[40]  D. Riddle,et al.  Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. , 1994, The Journal of biological chemistry.

[41]  J. Wozney,et al.  The bone morphogenetic protein family and osteogenesis , 1992, Molecular reproduction and development.

[42]  M. Urist,et al.  Bone: Formation by Autoinduction , 1965, Science.

[43]  M. MacCoss,et al.  Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. , 2007, Science.

[44]  C. Heldin,et al.  Non-Smad TGF-beta signals. , 2005, Journal of cell science.

[45]  O. Avsian-Kretchmer,et al.  Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. , 2004, Molecular endocrinology.

[46]  F. Pouliot,et al.  Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. , 2002, The Journal of endocrinology.

[47]  K. Miyazono.  TGF-beta signaling by Smad proteins. , 2000, Cytokine & growth factor reviews.

[48]  W. Raub.  From the National Institutes of Health. , 1990, JAMA.